Key Highlights

  • The London healthcare cohort enters the autumn of 2026 against a macro background that is steadier than it was two years ago but still demands selectivity. Sterling has remained a meaningful variable for companies in this group, many of which earn a large share of Revenue in US dollars or euros while reporting in pounds; currency movements can flatter or flatter-to-deceive reported growth, and several of the names discussed here make a point of separating constant-currency from reported figures.
  • Faron Pharmaceuticals (LSE:FARN): The most recent set-piece disclosure was Faron’s half-year results for the six months to 30 June 2026, published on 26 August 2026.
  • 4basebio (LSE:4BB): In July 2026 Richard Bungay joined as chief financial officer.
  • Cambridge Nutritional Sciences (LSE:CNSL): The company published its full-year results for the year ended 31 March 2026 via a regulatory announcement in September 2026.
  • Oxford Biomedica (LSE:OXB): In its half-year trading update, Oxford Biomedica reported H1 2026 revenue of around £80m, up 9% year on year, and reiterated full-year 2026 revenue guidance of £180m to £200m.
  • EKF Diagnostics Holdings (LSE:EKF): In its half-year report for the six months to 30 June 2026, EKF reported revenue of £25.0m, broadly flat year on year, with the gross Margin improving to 53% and net cash of £16.0m with no bank borrowings.
  • Inspiration Healthcare Group (LSE:IHC): Inspiration reported H1 results for the six months to 31 July 2026 on 8 September 2026.
  • Allergy Therapeutics (LSE:AGY): New immunotherapy data were presented at the AAAAI 2026 meeting in late February 2026, and the company issued subsequent positive-data updates across its grass-pollen and peanut programmes in mid-2026.
  • Hikma Pharmaceuticals (LSE:HIK): Hikma reported H1 2026 results for the six months to 30 June 2026.

UK-listed healthcare has rarely offered investors such a broad spread of Business models to study at once. On a single screen in September 2026 you can line up a clinical-stage immuno-oncology company with no revenue against a diversified generics group turning over billions of dollars a year, a synthetic-DNA toolmaker alongside a neonatal-ventilator manufacturer, and a cell and gene therapy contract manufacturer next to a micro-cap food-sensitivity testing business. The eight names examined here — Faron Pharmaceuticals, 4basebio, Cambridge Nutritional Sciences, Oxford Biomedica, EKF Diagnostics Holdings, Inspiration Healthcare Group, Allergy Therapeutics and Hikma Pharmaceuticals — span that whole range, and they deliberately cut across the London market’s two principal tiers.

That breadth matters for how this article should be read. The word “Top” in the headline is editorial framing for a group of companies worth following, not a ranking, a scoring system or any suggestion that one is a better holding than another. Likewise, “FTSE” is used broadly: only two of these companies, Oxford Biomedica and Hikma Pharmaceuticals, trade on the London Stock Exchange’s Main Market and sit within a recognised FTSE index (both are FTSE 250 constituents at the time of writing). The other six trade on AIM, London’s market for smaller and growing companies, and are not verified as current FTSE index constituents. Readers should keep that distinction front of mind throughout: an AIM micro-cap and a FTSE 250 member carry very different liquidity, disclosure cadence and risk characteristics, even when they operate in the same therapeutic area.

Why look at UK healthcare now? Several structural currents have kept the sector in investors’ sightlines through 2026. Ageing populations across developed economies continue to lift Demand for diagnostics, chronic-disease management and hospital consumables. The National Health Service remains a vast and demanding customer whose procurement priorities ripple through MedTech and diagnostics suppliers. Global pharmaceutical spending keeps expanding, supporting both the innovators chasing novel biology and the generics houses that Supply the everyday medicines underpinning health systems. At the same time, the funding environment for early-stage biotech has been more discerning than it was during the pandemic-era boom, rewarding companies that can point to data, partnerships or a clear route to cash generation, and punishing those that cannot.

Company-specific figures, dates, trial stages and index positions are drawn from each company’s own disclosures and a small number of market-data sources. Where a data point has not been confirmed, that is stated plainly rather than glossed over. The aim is to give readers a grounded, current picture of eight very different businesses and the things a careful observer might watch over the remainder of the month and beyond.

UK Healthcare Market Backdrop

The London healthcare cohort enters the autumn of 2026 against a macro background that is steadier than it was two years ago but still demands selectivity. Sterling has remained a meaningful variable for companies in this group, many of which earn a large share of revenue in US dollars or euros while reporting in pounds; currency movements can flatter or flatter-to-deceive reported growth, and several of the names discussed here make a point of separating constant-currency from reported figures. Interest rates, having risen sharply earlier in the decade, frame the Cost of Capital for cash-consuming biotech and the appetite of income-seeking investors for dividend-paying pharma. For a pre-revenue company burning cash, the rate environment is felt most acutely through the terms on which it can raise Equity or debt; for a profitable generics group, it shapes the calculus around leverage, Buybacks and dividends.

UK life-sciences policy continues to present the sector as a national strength, and the country retains genuine depth in academic research, clinical-trial infrastructure and specialist Manufacturing — cell and gene therapy, synthetic biology and diagnostics among them. Several companies in this article are, in effect, expressions of that industrial base: Oxford Biomedica and 4basebio both sell the tools and manufacturing capacity that other drug developers need, a “picks and shovels” position that can be less binary than betting on a single clinical readout. The NHS, for its part, remains simultaneously an opportunity and a constraint. Its scale makes it a prize customer for diagnostics and devices, but budget pressure and procurement timing can make revenue lumpy, a pattern visible in the tender-driven businesses covered below.

The tension between innovator and generic medicines is a defining feature of global pharma economics, and it runs directly through this cohort. At one end sit the companies chasing novel mechanisms — macrophage reprogramming in oncology, aluminium-free allergy immunotherapy — where success could be transformative but failure is a real possibility. At the other sits a diversified generics and injectables business whose value rests on manufacturing scale, regulatory filings and the steady churn of product launches as patents expire and shortages open up. Patent cycles, US generic-pricing dynamics and the perennial question of drug shortages in sterile injectables all bear on that end of the market.

Oncology and cell and gene therapy remain among the most closely watched areas of biomedical investment. The clinical promise of engineered cell therapies and gene-modifying treatments has driven demand for the specialised viral vectors and nucleic acids that make them, even as the end-market has shown cyclicality and as developers scrutinise costs. Diagnostics sits on a parallel track, with point-of-care testing, decentralised laboratory services and gut and metabolic health all drawing commercial interest, tempered by the reality that some consumer-facing testing is discretionary and sensitive to household budgets. Regulatory change is a live theme here too: the transition to the European Union’s In Vitro Diagnostic Regulation (IVDR) is reshaping the cost base and market access of diagnostics companies selling into Europe.

Medical devices and consumer health round out the picture. Device makers face long regulatory timelines — US Food and Drug Administration clearance can take years — and the trade-off between building scale and maintaining focus often surfaces as portfolio reshaping and divestment. Mergers and acquisitions remain a recurring feature across all these subsectors, whether as large pharma acquires pipeline assets, as manufacturers consolidate, or as smaller players divest non-core units to sharpen their strategic story. Finally, index dynamics themselves are part of the backdrop: the FTSE UK Index Series quarterly reviews can move demand from passive funds in or out of a stock overnight, as one company in this group discovered at the March 2026 review. Taken together, these themes argue for reading each company on its own merits rather than as a proxy for a single sector trade.

Faron Pharmaceuticals (LSE:FARN)

Company overview

Faron Pharmaceuticals is a clinical-stage immuno-oncology biotechnology company. Its shares trade as depositary interests on London’s AIM market and on Nasdaq First North in Helsinki; it is not a Main Market company, and while its AIM listing makes it eligible for the broad AIM All-Share universe, its membership of any specific AIM sub-index is not verified as a current FTSE index constituent. As at 13 August 2026, Market data put its Market Capitalisation at roughly £92m at a price of 41.0 pence, after a fall of around 81% over the preceding 52 weeks — a reminder that this is a highly volatile micro-cap with no product revenue. The company’s value rests almost entirely on a single clinical asset, bexmarilimab, an antibody that targets Clever-1 and is designed to reprogramme immunosuppressive macrophages so that the immune system can better attack tumours.

Latest September 2026 developments

The most recent set-piece disclosure was Faron’s half-year results for the six months to 30 June 2026, published on 26 August 2026. Shortly before that, on 27 July 2026, the company reported its first overall-survival data cut from the higher-risk myelodysplastic syndrome (HR-MDS) cohort, noting a median overall survival of 8.8 months in the biallelic TP53-mutated subgroup — a population that is typically very difficult to treat. On 13 July 2026 Faron gave an update on its investigator-initiated trial portfolio, spanning five separate studies, and on 3 August 2026 special rights were exercised in connection with bond amortisation. Each of these items speaks to a company managing an active clinical programme alongside a tightly watched balance sheet.

Major 2026 developments

The defining corporate event of the year was a €40m rights issue, announced on 9 February and closed on 9 April, which raised €40.1m gross. In April the company engaged the contract research organisation Parexel for its planned Phase 2b BEXERA trial. Maturing data from the BEXMAB study were presented at the European Hematology Association (EHA) Congress on 15 June, and the company made additions to its board and management through the year.

Products, pipeline and technology

Bexmarilimab is being developed across several fronts. The BEXMAB study is an ongoing Phase 1/2 trial combining bexmarilimab with azacitidine in higher-risk MDS and acute myeloid leukaemia (AML); Faron has reported a median complete-remission duration of 16.1 months in treatment-naïve HR-MDS patients. BEXERA is a planned Phase 2b trial — randomised, placebo-controlled, targeting around 90 patients across roughly 35 sites in the US, Europe and the UK in frontline, treatment-naïve higher-risk MDS — guided for initiation in the second half of 2026, though no confirmed date has been disclosed. A set of investigator-initiated Phase 2 trials rounds out the picture: BEXAR in soft-tissue sarcoma, BLAZE in anti-PD-1-refractory melanoma and non-small-cell lung cancer, and BEAM in AML after transplant.

Financial position

For the six months to 30 June 2026, Faron reported no revenue, Research and Development spending of €7.6m, an operating loss of €11.1m and a net loss of €8.5m, equating to a loss per share of €0.06. Cash stood at €32.0m at 30 June 2026, and total equity was positive at €11.6m. The company has said the April fundraising is intended to fund operations through major milestones in the second half of 2026 and beyond, although the precise cash runway has not been verified.

What investors may be watching

Observers are likely to focus on the initiation of, and first data from, the Phase 2b BEXERA trial, which the company has guided towards the second half of 2026 without a confirmed date. Further maturation of the HR-MDS overall-survival data, readouts from the investigator-initiated studies and any partnering activity would all add to the evidence base around bexmarilimab.

Key risks

Faron carries the concentration risk inherent in a single-asset biotech: the Investment case stands or falls with one molecule. As a cash-consuming micro-cap it is exposed to financing risk and potential dilution, a point underscored by the scale of the April rights issue relative to its market value. Early-stage efficacy signals, however encouraging, have not yet been confirmed in a pivotal setting, and the company’s finances carry going-concern sensitivity. No attributable broker views are available.

4basebio (LSE:4BB)

Company overview

4basebio operates as a biotechnology and life-science tools business specialising in synthetic DNA manufacturing and non-viral nucleic-acid delivery. The listed entity is 4basebio UK Societas, a European company (SE), and its regulatory announcements also use the name “4basebio PLC”; its ordinary shares, denominated at one euro, trade on AIM and it is not verified as a current FTSE index constituent. Market data recorded a market capitalisation of around £81.6m at 550.0 pence on 10 July 2026, on a small share count of roughly 15 million shares. The company makes enzymatic, cell-free synthetic DNA — branded “opDNA” — and mRNA for applications including gene therapy and editing, mRNA medicines, viral vectors and DNA and mRNA vaccines, and it complements this with synthetic nanoparticle delivery technology.

Latest September 2026 developments

In July 2026 Richard Bungay joined as chief financial officer. The company’s half-year report for the six months to 30 June 2026 was expected around late September; as at 11 September it had not been confirmed as published, so H1 2026 results were not yet confirmed published at the time of writing.

Major 2026 developments

The year brought significant Leadership change and capital activity. Dr Amy Walker was appointed chief executive in February 2026 and Christine Wolosin became chief commercial officer in March 2026. In April 2026 the company drew down €7m from a Deutsche Balaton facility, which it described as funding the business into late 2027. It also announced a Tier-1 pharmaceutical Partnership supporting an mRNA-vaccine Phase I/II programme and a multi-year clinical-supply agreement of approximately seven figures, and it set out plans to relocate to a new Cambridge manufacturing Facility in the late summer of 2026.

Products and commercial strategy

4basebio sits on the supply side of advanced therapeutics rather than developing its own drugs. Its GMP MIA(IMP) certification from the Medicines and Healthcare products Regulatory Agency, secured in April 2025, underpins its ability to supply material for clinical use. The company reported more than 125 customers and said it had supported four investigational new drug or clinical trial application filings during 2025. The commercial logic is to convert a growing pipeline of clinical-supply relationships into Recurring Revenue as customers’ programmes advance, with the new Cambridge facility intended to provide the capacity to do so.

Financial position

For the financial year ended 31 December 2025, 4basebio reported revenue of £1.7m, up 81%, with DNA sales doubling. Gross Profit rose to £0.974m from £0.630m, but the operating loss widened to £17.6m from £12.0m, and the loss per share was £1.09 against £0.94 the previous year. Cash stood at £17.8m at 31 December 2025, down from £34.6m a year earlier. The company noted that its new-business pipeline value grew 41% in the second half of 2025.

What investors may be watching

Points to monitor include the commissioning of the new Cambridge facility, progress in converting the clinical-supply pipeline into revenue, the Tier-1 mRNA-vaccine partner programme, and the timing and content of the H1 2026 results, the date of which is unverified.

Key risks

The gap between revenue of under £2m and an operating loss of around £17.6m highlights the early stage of commercialisation and the pace of cash consumption, with reliance on the Deutsche Balaton facility for funding. The synthetic-DNA market is competitive, and with a modest revenue base the business is exposed to customer concentration. No attributable broker views are available.

Cambridge Nutritional Sciences (LSE:CNSL)

Company overview

Cambridge Nutritional Sciences, formerly Omega Diagnostics Group plc, is a diagnostics and consumer-health company focused on food-sensitivity and gut-health testing. It trades on AIM and is not verified as a current FTSE index constituent. This is a micro-cap: Market data put its market capitalisation at around £4.2m at 1.70 pence on 9 July 2026. Its product range spans FoodPrint IgG food-reaction panels, the Food Detective point-of-care test, CNSLab Services for UK laboratory testing, and a newer product, GutDetective, which measures four gut biomarkers — calprotectin, pancreatic elastase, alpha-1 antitrypsin and secretory IgA. The company sells through distributors across the UK, India, Europe, the Americas, Asia and Africa and the Middle East.

Latest September 2026 developments

The company published its full-year results for the year ended 31 March 2026 via a regulatory announcement in September 2026. In June 2026 it appointed Erik Melgaard Pedersen, based in Denmark, as global sales director.

Major 2026 developments

The year was shaped by a revenue decline and a restructuring response. UK headcount was reduced from 76 to 58 full-time equivalents in March 2026, and the board took a 10% salary reduction. Operationally, manufacturing yields improved from 52% to 65%, a new laboratory information management system was introduced, and the CNSLab website was launched in March 2026. The company also renewed a five-year agreement with a UK white-label partner.

Products and commercial strategy

The strategy centres on self-pay and practitioner-led testing for food sensitivities and gut health, sold internationally through a distributor network. The launch of GutDetective broadens the biomarker menu beyond food-reaction panels into gut-function testing, while CNSLab Services and the refreshed CNSLab web presence support a direct laboratory-testing channel in the UK. A significant strategic objective is registration under the EU’s In Vitro Diagnostic Regulation, with completion targeted in 2027; the company frames IVDR not only as a compliance requirement but as an enabler of access to regulated markets and of new manufacturing technology.

Financial position

For the year to 31 March 2026, revenue fell 16.3% to £7.0m, while the gross margin improved 3.8 percentage points to 67.8%. Adjusted EBITDA swung to a loss of £0.4m from a £0.4m profit the previous year, and the operating loss before exceptionals was £1.2m. The statutory loss before tax was £4.4m, and the loss after tax £5.8m, after a £3.0m Goodwill Impairment and a £0.3m bad-debt provision. Reported loss per share was 2.4 pence, with an adjusted loss per share of 0.4 pence. Cash stood at £2.6m, down from £4.9m. The company’s going-concern assessment runs to 31 March 2028, and it said a reverse stress test showed headroom for a further revenue decline of around 15%.

What investors may be watching

Monitorable items include progress towards IVDR registration, targeted for completion in 2027, a recovery in European sales, growth in India and the UK, and any return to profitability, for which no date has been given.

Key risks

As a micro-cap with thin cash reserves, Cambridge Nutritional Sciences is sensitive to distributor losses, which it has flagged in the Americas and Asia, and to Tariff exposure. The IVDR transition carries cost, the going-concern position is sensitive, and demand for discretionary consumer testing can soften when household budgets tighten. No attributable broker views are available.

Oxford Biomedica (LSE:OXB)

Company overview

Oxford Biomedica is a biotechnology services business — specifically, a pure-play cell and gene therapy contract development and manufacturing organisation (CDMO) specialising in viral vectors including lentivirus, AAV and adenovirus. It trades on the Main Market and is a FTSE 250 constituent, though towards the lower end by size, a status worth re-checking against the latest FTSE Russell review. Market data recorded a market capitalisation of around £748.5m at 619.0 pence on 3 July 2026. Following a 2024 pivot out of in-house drug development, the company operates as a dedicated viral-vector manufacturer, with sites in Oxford in the UK, Bedford in Massachusetts in the US, and in France through ABL Europe, acquired in 2023. Its clients include Novartis, Bristol Myers Squibb and Sanofi.

Latest September 2026 developments

In its half-year trading update, Oxford Biomedica reported H1 2026 revenue of around £80m, up 9% year on year, and reiterated full-year 2026 revenue guidance of £180m to £200m. It signed 17 new clients in the first half, up more than 30% on its full-year 2025 tally, and entered a Commercial Supply Agreement with Bristol Myers Squibb for lentiviral vectors supporting BMS’s CAR-T portfolio. The revenue Backlog stood at around £193m, with a new-business pipeline of roughly $713m on a non-risk-adjusted basis, up 30% year on year. Interim results are scheduled for 22 September 2026 — a confirmed date and one of the nearest-term diary items in this group.

Major 2026 developments

The overarching corporate theme has been the transition to sustained profitability. The company has guided to 25% to 30% revenue growth in 2027 with double-digit EBITDA margins, framing 2026 as a staging post towards that goal.

Products and commercial strategy

As a CDMO, Oxford Biomedica makes money by manufacturing viral vectors for other companies’ therapies rather than by owning drugs itself — a position with a different risk profile from that of a clinical-stage developer. Its strategy turns on winning and retaining Blue-Chip clients, converting a large business-development pipeline into contracted backlog, and scaling its multi-site platform across the UK, US and France. The BMS commercial-supply win and the sharp rise in new-client signings illustrate the commercial engine the company is trying to build.

Financial position

H1 2026 revenue was around £80m. Gross cash was £75m at 30 June 2026, down from £97m at 31 December 2025, and net cash was £21m, down from £55m at the year-end — a drawdown consistent with investment during a scale-up phase. The company indicated that forecast 2026 revenue of around £165m was already covered by contracted orders of roughly £97m.

What investors may be watching

The 22 September 2026 interim results are the obvious near-term focus. Beyond that, observers may track conversion of the $713m pipeline into backlog and revenue, delivery against the £180m to £200m full-year 2026 guidance and the 2027 targets, and any further commercial-supply wins.

Key risks

Client concentration is a genuine consideration, with Novartis, BMS and Sanofi prominent among customers. The cell and gene therapy end-market has shown cyclicality, there is execution and margin risk in ramping to sustained profitability, and cash is being drawn down during the scale-up. On broker views, Peel Hunt was reported by the aggregator MarketBeat to have reiterated a “Buy” stance on 4 August 2025; that is aggregator-sourced and dated to 2025, and is mentioned here only with those caveats.

EKF Diagnostics Holdings (LSE:EKF)

Company overview

EKF Diagnostics Holdings is a diagnostics company combining point-of-care testing with life-science manufacturing, including enzyme production and contract fermentation. It trades on AIM and is not verified as a current FTSE index constituent. Market data put its market capitalisation at around £109.4m at 25.4 pence on 10 July 2026. The business runs two divisions. Point-of-Care supplies haemoglobin and haematology analysers — the Hemo Control and DiaSpect devices, HbA1c testing and the Biosen platform — while Life Sciences manufactures enzymes, produces β-hydroxybutyrate for ketone testing, and offers contract fermentation and CDMO services. Geographically, the US accounts for around 43% of revenue and Germany around 14%, with further sales across Russia, Peru, Africa and Asia.

Latest September 2026 developments

In its half-year report for the six months to 30 June 2026, EKF reported revenue of £25.0m, broadly flat year on year, with the gross margin improving to 53% and net cash of £16.0m with no bank borrowings. Life Sciences revenue rose 20% and β-hydroxybutyrate revenue was up 4%, while high-volume point-of-care tenders were weighted towards the second half. The company completed £1.4m of buybacks and reiterated its confidence in full-year 2026 revenue and adjusted EBITDA growth in line with market expectations.

Major 2026 developments

EKF has been expanding capacity, targeting an increase of around 30% in cuvette production through 2027, and continuing a buyback programme that ran to £5.0m in 2025 and has carried into 2026. Strategically, it is seeking to grow its US haemoglobin point-of-care share, including in blood banks, and to build out its Life Sciences CDMO offering.

Products and commercial strategy

The dual-division model gives EKF both a recurring diagnostics franchise, where analysers drive demand for consumables, and a manufacturing arm selling enzymes and fermentation services. The planned multi-analyte point-of-care products, expected in 2027 and 2028, and the cuvette capacity expansion are intended to support the point-of-care side, while Life Sciences is positioned to win contract work and supply β-hydroxybutyrate into ketone testing.

Financial position

For the year ended 31 December 2025, revenue rose 2.8% to £51.6m, with a gross margin of 51% and adjusted EBITDA up 9.3% to £12.4m. Operating profit was £7.0m and profit before tax £7.1m, while Earnings Per Share were 0.47 pence, down from 1.38 pence in 2024 on non-cash and Amortisation items, including £1.4m of accelerated R&D amortisation. Net cash was £15.8m, or £13.7m excluding restricted Russian cash, and no Dividend was paid.

What investors may be watching

Items to monitor include conversion of the second-half-weighted point-of-care tenders, delivery against full-year 2026 guidance, completion of the capacity expansion through 2027, the planned new multi-analyte point-of-care products for 2027 and 2028, and Life Sciences CDMO wins.

Key risks

EKF carries restricted Russian cash of around £2.1m and broader Russia exposure of about 8% of revenue. Tender timing can make revenue lumpy, top-line growth is modest, and the company is exposed to US dollar and euro currency movements. No attributable broker views are available; an available “Buy” note is not attributable and is omitted.

Inspiration Healthcare Group (LSE:IHC)

Company overview

Inspiration Healthcare Group is a medical-technology company focused on neonatal intensive care. It trades on AIM and is not verified as a current FTSE index constituent. Market data recorded a market capitalisation of around £17.5m at 20.0 pence on 7 July 2026, placing it among the micro-caps in this group. The company makes neonatal medical technology — ventilators, respiratory-support equipment and single-use devices under the SLE Brand — and US ventilators through Airon, and it operates a medtech distribution arm. It manufactures in Croydon in the UK and in Florida in the US, and sells in more than 75 countries.

Latest September 2026 developments

Inspiration reported H1 results for the six months to 31 July 2026 on 8 September 2026. Revenue was around £22m, down year on year because the prior period had included one-off export contracts. Stripping those out, underlying SLE revenue rose 38%, Airon contributed £1.6m, up 40%, and medtech distribution grew 7%. The company said it expects to finish the year slightly ahead of company-compiled market expectations on the strength of its order book. H1 profit, EBITDA and cash figures were not detailed and remain unverified for the period.

Major 2026 developments

Full-year results for the year ended 31 January 2026 were published on 16 June 2026. The company agreed to divest its infusion distribution business to Micrel Medical Devices SA, effective 31 January 2027, sharpening its focus on neonatal care. Its US FDA filing is now expected in late 2027.

Products and commercial strategy

The strategy is increasingly concentrated on the neonatal franchise. The SLE brand anchors the core ventilator and respiratory-support range, Airon adds a US ventilator presence, and the planned divestment of infusion distribution is intended to remove a non-core activity and let management focus on neonatal technology. Manufacturing in both the UK and the US supports a geographically broad customer base.

Financial position

For the year ended 31 January 2026, revenue rose 24% to £47.5m and gross profit rose 27% to £20.8m, a margin of 43.7%. Adjusted EBITDA improved to £2.8m from £0.2m the previous year, and adjusted operating profit was £0.8m against a £1.9m loss. The operating loss narrowed sharply to £0.1m from £14.7m, the prior year having been hit by impairments, and the net loss was £1.04m, a basic loss per share of 1.16 pence. Net Debt excluding IFRS 16 fell 39% to £5.1m, operating cash inflow was £7.5m, and inventory was cut 33% to £8.8m. No dividend was paid, with the suspension maintained.

What investors may be watching

Points to monitor include the full-year 2027 outturn against the “slightly ahead” guidance, the completion and financial impact of the Micrel infusion divestment effective 31 January 2027, the US FDA filing expected in late 2027, and progress on net-debt reduction and any dividend resumption, for which no date has been set.

Key risks

Revenue can be lumpy because of one-off export contracts, as this year’s H1 comparison showed. The company is a micro-cap with the attendant Liquidity considerations, it continues to report net losses, it will rely heavily on the SLE neonatal Franchise after the divestment, and the FDA timeline could slip. No attributable broker views are available.

Allergy Therapeutics (LSE:AGY)

Company overview

Allergy Therapeutics is a pharmaceutical and biotechnology company specialising in allergy immunotherapy, sometimes described as allergy vaccines. It trades on AIM, with a US over-the-counter listing under AGYTF, and is not verified as a current FTSE index constituent. Market data recorded a market capitalisation of around £300.8m at 5.0 pence on 10 September 2026, within a 52-week range of 4.50 to 12.10 pence. The combination of a very low pence price and a market capitalisation above £300m reflects a large share count following a 2023 Recapitalisation led by Southern Fox, alongside heavy historical dilution; the share count and market capitalisation should be re-verified against the latest regulatory announcement. The company develops and markets subcutaneous, short-course, aluminium-free allergy immunotherapies, with commercial products concentrated in Germany and Europe and lead clinical programmes in grass-pollen and peanut allergy.

Latest September 2026 developments

New immunotherapy data were presented at the AAAAI 2026 meeting in late February 2026, and the company issued subsequent positive-data updates across its grass-pollen and peanut programmes in mid-2026. The primary source for the mid-2026 update returned an access error, so the specifics of that update should be treated as unverified pending the underlying regulatory announcement.

Major 2026 developments

A landmark event was securing German Marketing authorisation for Grassmuno (Grass MATA MPL), with commercial launch in Germany in January 2026 and reported strong early uptake among clinicians. On the financing side, the company put in place a £40m senior secured facility from Hayfin and repaid Shareholder debt via Warrant exercises. For the first half of its 2026 financial year, the six months to 31 December 2025, it reported revenue of £36.3m, up 7%, and an operating loss before R&D of £2.5m.

Products, pipeline and technology

Grass MATA MPL completed a pivotal adult Phase III trial, G306, which met its primary endpoint with a statistically significant 22.5% reduction in a combined symptom-and-medication score versus placebo; a paediatric Phase III is ongoing with positive safety data reported. That product is now approved and launched in Germany as Grassmuno. The VLP Peanut programme is in Phase I/IIa, having met its primary safety endpoint and shown positive tolerability alongside interim immunomodulatory and biomarker data. The company’s platform emphasis on aluminium-free, short-course subcutaneous immunotherapy is central to its differentiation.

Financial position

For H1 of financial year 2026, revenue was £36.3m, up 7%, with an operating loss before R&D of £2.5m. The £40m Hayfin facility is in place and shareholder debt has been cleared, but detailed full-year cash and net-debt figures are unverified.

What investors may be watching

Monitorable items include the commercial ramp of Grassmuno in Germany and any additional European approvals or launches, further regulatory submissions for Grass MATA MPL in the US and EU where timing is not confirmed, completion of the paediatric Phase III, and progression of the VLP Peanut programme.

Key risks

The Capital Structure is highly dilutive and the company depends on refinancing, notably the Hayfin facility, with a controlling shareholder, Southern Fox, exerting influence. Clinical and regulatory execution carries risk, revenue is seasonal and driven by the pollen cycle, and the company has a going-concern history. No attributable broker views are available; an available “Sell” note is not attributable and is omitted.

Hikma Pharmaceuticals (LSE:HIK)

Company overview

Hikma Pharmaceuticals is a diversified pharmaceutical company spanning generics, generic injectables and branded medicines. It trades on the Main Market and is a FTSE 250 constituent, having been relegated from the FTSE 100 to the FTSE 250 at the March 2026 quarterly review, announced on 4 March 2026. Its market capitalisation was around £3.18bn to £3.33bn in September 2026, a sub-£4bn level consistent with the relegation. The business runs three segments: Generic Injectables, largely in the US; Generics, the US oral and other “Hikma Rx” business; and Branded, focused on the Middle East and North Africa (MENA) region.

Latest September 2026 developments

Hikma reported H1 2026 results for the six months to 30 June 2026. Group revenue was $1,728m, up 4%, or 3% on a constant-currency basis. By segment, Branded revenue rose 15% to $502m, Injectables was flat at $685m, and Generics was flat at $520m. Core operating profit rose 9% to $405m, while reported operating profit rose 30% to $336m. Core earnings per share were 128 cents, up 5%, and reported earnings per share were 103 cents, down 5%. Net debt to core EBITDA stood at 1.9 times, up from 1.6 times at 31 December 2025. The Interim Dividend was 38 cents, up 6%, and $227m of a $250m buyback had been completed as at 5 August 2026. The company reiterated full-year 2026 guidance of constant-currency revenue growth of 2% to 4% and core operating profit of $720m to $770m, and on 7 August 2026 it appointed Tobias Hestler as an independent non-executive director.

Major 2026 developments

The FTSE 100 to FTSE 250 relegation in March 2026 was the year’s most notable index event. Operationally, Hikma delivered 43 product launches and 48 submissions in the first half, increased R&D spending by 18%, and signed 10 new MENA partnerships, alongside the ongoing $250m buyback. At the full-year 2025 results on 26 February 2026, the company reported revenue of around $3,349m, up 7%, core operating profit of $741m and a total dividend of 84 cents, and announced that Said Darwazah would focus solely on the chief executive role.

Products and commercial strategy

Hikma’s model rests on manufacturing breadth and a steady cadence of product launches and regulatory submissions across its three segments. Generic Injectables and Generics anchor a large US presence, where the company can benefit from drug-shortage dynamics and the regular opening of opportunities as patents expire, while the Branded segment provides growth and partnerships in the MENA region. The H1 pattern, with Branded up 15% and the two US-centric segments flat, illustrates where the growth currently sits.

Financial position

H1 2026 group revenue was $1,728m with core operating profit of $405m. Leverage, at 1.9 times net debt to core EBITDA, rose over the half as the buyback and dividend were funded, but remained at a moderate level. The company pays a progressive dividend — the interim was lifted 6% to 38 cents — and the $250m buyback was most of the way complete by early August.

What investors may be watching

Items to monitor include the full-year 2026 results, expected around February 2027 with no exact date announced, delivery against the $720m to $770m core-operating-profit guidance, the injectables pipeline and launches together with any US shortage tailwinds, completion of the buyback, any M&A or partnership activity, and the possibility of FTSE 100 re-promotion should the market capitalisation recover.

Key risks

Hikma faces US generic-pricing pressure and competition, and currently relies on Branded to carry growth while Injectables and Generics are flat. It is exposed to MENA currency and political risk, to its Leverage trajectory, and to the loss of FTSE 100 index-fund demand following relegation. Potential US pharmaceutical tariffs are a further consideration. No attributable broker views are available.

What Should Investors Watch During the Rest of September 2026?

The clearest diary item for the remainder of the month is Oxford Biomedica’s interim results, scheduled for 22 September 2026 — a confirmed date. Those results will put detail behind the half-year trading update’s headline figures, including the roughly £80m of H1 revenue, the £180m to £200m full-year guidance, the revenue backlog of around £193m and the near-$713m business-development pipeline, and will be read alongside the company’s stated ambition of sustained profitability and 25% to 30% revenue growth in 2027.

For 4basebio, the half-year report for the six months to 30 June 2026 was expected around late September, but as at 11 September it had not been confirmed as published, and no firm date has been verified. Investors following the company will be watching both for the timing of that release and for any update on the new Cambridge manufacturing facility, which the company planned to occupy in the late summer of 2026, and on its Tier-1 mRNA-vaccine partnership.

Several other companies have recently reported and so are in a quieter part of their disclosure cycle. Faron published H1 results on 26 August 2026, with its near-term interest centring on the guided-but-undated initiation of the Phase 2b BEXERA trial in the second half of the year and on further maturation of the HR-MDS survival data. Inspiration Healthcare reported H1 results on 8 September 2026 and guided to a full-year outcome slightly ahead of company-compiled expectations; the next structural events for it are the Micrel infusion divestment, effective 31 January 2027, and the US FDA filing expected in late 2027. Cambridge Nutritional Sciences published its full-year results via a regulatory announcement in September 2026, with IVDR registration targeted for 2027. EKF Diagnostics, having reported H1 2026, has flagged that its high-volume point-of-care tenders are weighted to the second half, so tender conversion is the thing to watch rather than a fixed date.

Allergy Therapeutics issued positive data updates across its grass-pollen and peanut programmes in mid-2026, though the specifics of that update are unverified pending the underlying regulatory announcement; for the rest of September, attention is likely to rest on the commercial progress of Grassmuno in Germany. Hikma reported H1 2026 results on 6 August 2026 and reiterated full-year guidance; its next scheduled set-piece is full-year 2026 results, expected around February 2027, with no exact date announced, and in the interim the completion of its $250m buyback and any index-review developments are the obvious watch-points.

On the macro side, investors will as ever weigh the interest-rate and sterling backdrop, the pace of NHS and international procurement, and the next FTSE UK Index Series quarterly review, which can shift passive-fund demand for the Main Market names. None of these is a guaranteed catalyst, and where no official date exists it has been said so rather than implied.

Conclusion

The eight companies gathered here do not form a single trade or a ranked list; they are a cross-section of how UK-listed healthcare expresses itself in September 2026, from a FTSE 250 generics group turning over well over three billion dollars a year to an AIM micro-cap diagnostics business valued at a few million pounds. Read together, they illustrate the themes running through the sector: the enduring pull of ageing demographics and NHS demand, the contrast between innovator risk and generic-scale economics, the rise of “picks and shovels” suppliers to advanced therapies, the reshaping of portfolios through divestment and focus, and the ever-present influence of funding conditions, currency and index membership on how these shares behave.

Two distinctions deserve repeating. The first is structural: only Oxford Biomedica and Hikma sit on the Main Market and within a FTSE index, both in the FTSE 250 at the time of writing, while the other six trade on AIM and are not verified as current FTSE index constituents. That difference shapes liquidity, disclosure frequency and the kind of investor likely to hold the shares, and it should temper any tendency to treat the group as interchangeable.

What the group does offer is a set of concrete, near-term things to observe — a confirmed interim-results date for Oxford Biomedica on 22 September, a guided but undated Phase 2b trial start at Faron, an IVDR registration target at Cambridge Nutritional Sciences, a divestment completion and FDA filing ahead at Inspiration Healthcare, a German commercial ramp at Allergy Therapeutics, tender conversion at EKF, a possible facility commissioning at 4basebio, and guidance delivery and buyback completion at Hikma. Each carries its own, company-specific risks, from single-asset concentration and going-concern sensitivity at the smaller end to generic-pricing pressure and index-demand effects at the larger. For readers building their own view, the sensible course is to go back to each company’s primary disclosures, check the figures and dates against the latest announcements, and weigh the risks as carefully as the opportunities. This article is general information to support that work, not a substitute for it.